Low and variable tumor reactivity of the intratumoral T

Nature Medicine

25, 89-94

DOI: 10.1038/s41591-018-0266-5

Citation Report

#	Article	IF	Citations
1	Development of a Human Cytomegalovirus (HCMV)-Based Therapeutic Cancer Vaccine Uncovers a Previously Unsuspected Viral Block of MHC Class I Antigen Presentation. Frontiers in Immunology, 2019, 10, 1776.	2.2	15
2	T cell receptorâ€based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunological Reviews, 2019, 290, 127-147.	2.8	180
3	Advancing cancer immunotherapy: a vision for the field. Genome Medicine, 2019, 11, 51.	3.6	12
4	Clonal replacement of tumor-specific T cells following PD-1 blockade. Nature Medicine, 2019, 25, 1251-1259.	15.2	974
5	Single-Cell High-Throughput Technologies in Cerebrospinal Fluid Research and Diagnostics. Frontiers in Immunology, 2019, 10, 1302.	2.2	12
6	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8 ⁺ T cell responses. Science Translational Medicine, 2019, 11, .	5.8	66
7	MildÂphotothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy. Nature Communications, 2019, 10, 4871.	5.8	377
8	An innate-like VÎ´1 ⁺ Î³Î´ T cell compartment in the human breast is associated with remission in triple-negative breast cancer. Science Translational Medicine, 2019, 11, .	5.8	110
9	Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. British Journal of Cancer, 2019, 121, 809-818.	2.9	232
10	Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?. Frontiers in Immunology, 2019, 10, 1816.	2.2	52
11	Improving cancer immunotherapy through nanotechnology. Nature Reviews Cancer, 2019, 19, 587-602.	12.8	426
12	Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma. , 2019, 7, 232.		20
13	Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?. Cancer Cell, 2019, 36, 215-217.	7.7	29
14	Defining â€˜T cell exhaustionâ€™. Nature Reviews Immunology, 2019, 19, 665-674.	10.6	879
15	Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nature Medicine, 2019, 25, 1549-1559.	15.2	147
16	Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nature Communications, 2019, 10, 567.	5.8	193
17	Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation. Clinical Cancer Research, 2019, 25, 6392-6405.	3.2	37
18	Determinants for Neoantigen Identification. Frontiers in Immunology, 2019, 10, 1392.	2.2	99

#	Article	IF	Citations
19	Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections. Current Opinion in Immunology, 2019, 58, 98-103.	2.4	83
20	Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy. Molecular Aspects of Medicine, 2019, 69, 123-129.	2.7	30
21	Î²-Catenin Activation Promotes Immune Escape and Resistance to Antiâ€“PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1124-1141.	7.7	498
22	Tertiary lymphoid structures in the era of cancer immunotherapy. Nature Reviews Cancer, 2019, 19, 307-325.	12.8	879
23	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nature Medicine, 2019, 25, 767-775.	15.2	282
24	Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Nonâ€“Small Cell Lung Cancer. Cancer Immunology Research, 2019, 7, 896-909.	1.6	64
25	Clinically Relevant Immune Responses against Cytomegalovirus: Implications for Precision Medicine. International Journal of Molecular Sciences, 2019, 20, 1986.	1.8	6
26	Applications of molecular engineering in Tâ€cellâ€based immunotherapies. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2019, 11, e1557.	3.3	6
27	Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer. OncoImmunology, 2019, 8, e1586409.	2.1	20
28	Going Beyond the Sequences: TCR Binding Patterns at the Service of Cancer Detection. Cancer Research, 2019, 79, 1299-1301.	0.4	4
29	Cellular crosstalk mediating immune evasion in pancreatic cancer microenvironment. Annals of Pancreatic Cancer, 0, 2, 13-13.	1.2	0
30	Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell, 2019, 179, 1177-1190.e13.	13.5	259
31	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23662-23670.	3.3	40
32	Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4. Genome Medicine, 2019, 11, 87.	3.6	44
33	Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response. Radiology Imaging Cancer, 2019, 1, e190031.	0.7	22
34	T-cell Receptors Engineered De Novo for Peptide Specificity Can Mediate Optimal T-cell Activity without Self Cross-Reactivity. Cancer Immunology Research, 2019, 7, 2025-2035.	1.6	10
35	One-step artificial antigen presenting cell-based vaccines induce potent effector CD8 T cell responses. Scientific Reports, 2019, 9, 18949.	1.6	10
36	The activation of bystander CD8+ T cells and their roles in viral infection. Experimental and Molecular Medicine, 2019, 51, 1-9.	3.2	100

#	Article	IF	Citations
37	Clonal replacement of novel T cells: a new phenomenon in the tumor microenvironment following PD-1 blockade. Signal Transduction and Targeted Therapy, 2019, 4, 43.	7.1	11
38	Harnessing innate immunity in cancer therapy. Nature, 2019, 574, 45-56.	13.7	533
39	Developing neoantigen-targeted T cellâ€“based treatments for solid tumors. Nature Medicine, 2019, 25, 1488-1499.	15.2	173
40	T-Cell Receptorâ€“Based Immunotherapy for Hematologic Malignancies. Cancer Journal (Sudbury, Mass), 2019, 25, 179-190.	1.0	28
41	Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. Cell, 2019, 176, 775-789.e18.	13.5	760
42	A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response. Journal of Investigative Dermatology, 2020, 140, 869-877.e16.	0.3	15
43	Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes. Clinical Cancer Research, 2020, 26, 505-517.	3.2	26
44	Distinct epigenetic features of tumor-reactive CD8+ T cells in colorectal cancer patients revealed by genome-wide DNA methylation analysis. Genome Biology, 2020, 21, 2.	3.8	77
45	Tumor organoidâ€“T-cell coculture systems. Nature Protocols, 2020, 15, 15-39.	5.5	189
46	Using single-cell technologies to map the human immune system â€” implications for nephrology. Nature Reviews Nephrology, 2020, 16, 112-128.	4.1	39
47	Immune profiling before treatment is predictive of TLR9-induced antitumor efficacy. Biomaterials, 2020, 263, 120379.	5.7	0
48	Detecting Tumor Antigen-Specific T Cells via Interaction-Dependent Fucosyl-Biotinylation. Cell, 2020, 183, 1117-1133.e19.	13.5	66
49	Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma. Cancers, 2020, 12, 3344.	1.7	19
50	Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases. , 2020, 8, e001478.		22
51	Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma. Nature Communications, 2020, 11, 5992.	5.8	87
52	Applications of Single-Cell Omics to Dissect Tumor Microenvironment. Frontiers in Genetics, 2020, 11, 548719.	1.1	18
53	A Tâ€cell reporter platform for highâ€throughput and reliable investigation of TCR function and biology. Clinical and Translational Immunology, 2020, 9, e1216.	1.7	15
54	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705.		20

#	Article	IF	Citations
55	Antitumour dendritic cell vaccination in a priming and boosting approach. Nature Reviews Drug Discovery, 2020, 19, 635-652.	21.5	148
56	CD39 Identifies the CD4+ Tumor-Specific T-cell Population in Human Cancer. Cancer Immunology Research, 2020, 8, 1311-1321.	1.6	84
57	P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors. Cancer Research, 2020, 80, 3906-3919.	0.4	36
58	Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human VÎ³2VÎ´2 T Cells. Frontiers in Immunology, 2020, 11, 1405.	2.2	16
59	Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy. Tumori, 2020, 107, 030089162094038.	0.6	8
60	Resident Memory T Cells in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1273, 39-68.	0.8	3
61	Helpless Priming Sends CD8+ T Cells on the Road to Exhaustion. Frontiers in Immunology, 2020, 11, 592569.	2.2	25
62	Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPinÃ® Proteins. Journal of Immunology Research, 2020, 2020, 1-12.	0.9	8
63	Breaking Bottlenecks for the TCR Therapy of Cancer. Cells, 2020, 9, 2095.	1.8	35
64	TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. Frontiers in Immunology, 2020, 11, 1689.	2.2	63
65	Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade. Science Translational Medicine, 2020, 12, .	5.8	34
66	De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection. Science Translational Medicine, 2020, 12, .	5.8	59
67	Platelets are recruited to hepatocellular carcinoma tissues in a CX3CL1â€CX3CR1 dependent manner and induce tumour cell apoptosis. Molecular Oncology, 2020, 14, 2546-2559.	2.1	19
68	Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science, 2020, 370, 1328-1334.	6.0	273
69	Some Like It Sweet: Dendritic Cells Add Sugar to Their T(ea). Cell, 2020, 183, 847-849.	13.5	0
70	T cell factor 1: A master regulator of the T cell response in disease. Science Immunology, 2020, 5, .	5.6	85
71	Needle in a Haystack: The NaÃ¯ve Repertoire as a Source of T Cell Receptors for Adoptive Therapy with Engineered T Cells. International Journal of Molecular Sciences, 2020, 21, 8324.	1.8	5
72	Antiviral T Cell Receptor Complementarity Determining Region-3 Sequences Are Associated with a Worse Cancer Outcome: A Pancancer Analysis. Viral Immunology, 2020, 33, 404-412.	0.6	5

#	Article	IF	Citations
73	Phosphoproteomics of CD2 signaling reveals AMPK-dependent regulation of lytic granule polarization in cytotoxic T cells. Science Signaling, 2020, 13, .	1.6	18
74	PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nature Cancer, 2020, 1, 681-691.	5.7	240
75	New Insights into the Immune System Using Dirty Mice. Journal of Immunology, 2020, 205, 3-11.	0.4	59
76	Integrating context of tumor biology and vaccine design to shape multidimensional immunotherapies. Future Drug Discovery, 2020, 2, FDD25.	0.8	1
77	Massively parallel interrogation and mining of natively paired human TCRÎ±Î² repertoires. Nature Biotechnology, 2020, 38, 609-619.	9.4	34
78	Adoptive Cell Therapyâ€"Harnessing Antigen-Specific T Cells to Target Solid Tumours. Cancers, 2020, 12, 683.	1.7	34
79	Microbiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer. Microbiology and Molecular Biology Reviews, 2020, 84, .	2.9	37
80	Tumor Microenvironment. Cancer Treatment and Research, 2020, , .	0.2	12
81	Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal. Frontiers in Immunology, 2020, 11, 1215.	2.2	32
82	Inhibition of Aurora-A Promotes CD8+ T-Cell Infiltration by Mediating IL10 Production in Cancer Cells. Molecular Cancer Research, 2020, 18, 1589-1602.	1.5	13
83	The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular and Molecular Immunology, 2020, 17, 807-821.	4.8	1,136
84	Endogenous retroviral proteins provide an immunodominant but not requisite antigen in a murine immunotherapy tumor model. OncoImmunology, 2020, 9, 1758602.	2.1	12
85	Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, , .	0.8	3
86	Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature, 2020, 579, 274-278.	13.7	439
87	Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nature Biotechnology, 2020, 38, 420-425.	9.4	48
88	Microbes as Master Immunomodulators: Immunopathology, Cancer and Personalized Immunotherapies. Frontiers in Cell and Developmental Biology, 2019, 7, 362.	1.8	7
89	Biotechnologies to tackle the challenge of neoantigen identification. Current Opinion in Biotechnology, 2020, 65, 52-59.	3.3	25
90	Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. Nature Cancer, 2020, 1, 197-209.	5.7	30

#	Article	IF	Citations
91	Methods to edit T cells for cancer immunotherapy. Methods in Enzymology, 2020, 631, 107-135.	0.4	5
92	The Adaptive and Innate Immune Cell Landscape of Uterine Leiomyosarcomas. Scientific Reports, 2020, 10, 702.	1.6	14
93	Top 10 Challenges in Cancer Immunotherapy. Immunity, 2020, 52, 17-35.	6.6	1,177
94	Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nature Communications, 2020, 11, 661.	5.8	124
95	RNA-Seq-Based TCR Profiling Reveals Persistently Increased Intratumoral Clonality in Responders to Anti-PD-1 Therapy. Frontiers in Oncology, 2020, 10, 385.	1.3	11
96	Downregulation of ubiquitin-specific protease 2 possesses prognostic and diagnostic value and promotes the clear cell renal cell carcinoma progression. Annals of Translational Medicine, 2020, 8, 319-319.	0.7	18
97	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 1327-1337.	3.2	90
98	Targeting tumor microenvironment in ovarian cancer: Premise and promise. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1873, 188361.	3.3	105
99	Eomes identifies thymic precursors of self-specific memory-phenotype CD8+ T cells. Nature Immunology, 2020, 21, 567-577.	7.0	55
100	A facile technology for the high-throughput sequencing of the paired VH:VL and TCRÎ²:TCRÎ± repertoires. Science Advances, 2020, 6, eaay9093.	4.7	18
101	Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 321-321.	0.7	7
102	Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer. International Immunopharmacology, 2020, 84, 106506.	1.7	12
103	Deciphering the transcriptomic landscape of tumor-infiltrating CD8 lymphocytes in B16 melanoma tumors with single-cell RNA-Seq. OncoImmunology, 2020, 9, 1737369.	2.1	42
104	The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones. Clinical Cancer Research, 2020, 26, 4289-4301.	3.2	46
105	Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study. Journal of Hematology and Oncology, 2020, 13, 37.	6.9	32
106	PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15. Cellular and Molecular Immunology, 2021, 18, 385-397.	4.8	37
107	Transcriptome Profiling Identifies TIGIT as a Marker of Tâ€Cell Exhaustion in Liver Cancer. Hepatology, 2021, 73, 1399-1418.	3.6	61
108	Ag2S nanoparticle-mediated multiple ablations reinvigorates the immune response for enhanced cancer photo-immunotherapy. Biomaterials, 2021, 264, 120451.	5.7	53

#	Article	IF	Citations
109	Nicotine exhausts CD8+ T cells against tumor cells through increasing miR-629-5p to repress IL2RB-mediated granzyme B expression. Cancer Immunology, Immunotherapy, 2021, 70, 1351-1364.	2.0	6
110	Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. Nature Reviews Clinical Oncology, 2021, 18, 244-256.	12.5	138
111	The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies. Seminars in Cancer Biology, 2021, 72, 76-89.	4.3	87
112	T Cells Expanded from PD-1+ Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating Lymphocytes. Cancer Research, 2021, 81, 2184-2194.	0.4	18
113	The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes. British Journal of Cancer, 2021, 124, 1138-1149.	2.9	14
114	Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies. OncoImmunology, 2021, 10, 1869389.	2.1	14
115	Singleâ€cell transcriptome analysis revealed the heterogeneity and microenvironment of gastrointestinal stromal tumors. Cancer Science, 2021, 112, 1262-1274.	1.7	18
116	Cell therapies in ovarian cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110083.	1.4	20
117	Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nature Medicine, 2021, 27, 212-224.	15.2	376
118	Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nature Communications, 2021, 12, 1047.	5.8	96
119	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. Cancer Discovery, 2021, 11, 1524-1541.	7.7	103
120	TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nature Medicine, 2021, 27, 419-425.	15.2	156
121	Implication of CD69⁺CD103⁺ tissueâ€residentâ€like CD8⁺ T cells as a potential immunotherapeutic target for cholangiocarcinoma. Liver International, 2021, 41, 764-776.	1.9	18
122	Self-Replicating RNAs Drive Protective Anti-tumor T Cell Responses to Neoantigen Vaccine Targets in a Combinatorial Approach. Molecular Therapy, 2021, 29, 1186-1198.	3.7	14
123	Promises and challenges of adoptive T-cell therapies for solid tumours. British Journal of Cancer, 2021, 124, 1759-1776.	2.9	113
124	HLA-Eâ€“restricted, Gag-specific CD8 ⁺ T cells can suppress HIV-1 infection, offering vaccine opportunities. Science Immunology, 2021, 6, .	5.6	35
125	TCR Î² chainâ€“directed bispecific antibodies for the treatment of T cell cancers. Science Translational Medicine, 2021, 13, .	5.8	30
126	DeepTCR is a deep learning framework for revealing sequence concepts within T-cell repertoires. Nature Communications, 2021, 12, 1605.	5.8	107

#	Article	IF	Citations
127	Global analysis of shared TÂcell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity, 2021, 54, 586-602.e8.	6.6	80
128	Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer. Frontiers in Oncology, 2021, 11, 537735.	1.3	5
129	Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches. Cancer Discovery, 2021, 11, 1024-1039.	7.7	56
130	Moving Toward the Ideal Autologous Adoptive T-cell Therapy for Cancer. Cancer Research, 2021, 81, 1940-1941.	0.4	1
131	Leveraging Single-Cell Sequencing for Chimeric Antigen Receptor T Cell Therapies. Trends in Biotechnology, 2021, 39, 1308-1320.	4.9	18
132	STARTRAC analyses of scRNAseq data from tumor models reveal T cell dynamics and therapeutic targets. Journal of Experimental Medicine, 2021, 218, .	4.2	15
133	Cancer therapy in mice using a pure population of CD8+â€‰T cell specific to the AH1 tumor rejection antigen. Cancer Immunology, Immunotherapy, 2021, 70, 3183-3197.	2.0	5
134	IL-7 coupled with IL-12 increases intratumoral T cell clonality, leading to complete regression of non-immunogenic tumors. Cancer Immunology, Immunotherapy, 2021, 70, 3557-3571.	2.0	11
135	Leveraging Single-Cell Approaches in Cancer Precision Medicine. Trends in Cancer, 2021, 7, 359-372.	3.8	18
136	The Dynamic Entropy of Tumor Immune Infiltrates: The Impact of Recirculation, Antigen-Specific Interactions, and Retention on T Cells in Tumors. Frontiers in Oncology, 2021, 11, 653625.	1.3	12
137	Modulation of the tumor micro-environment by CD8+ T cell-derived cytokines. Current Opinion in Immunology, 2021, 69, 65-71.	2.4	14
138	Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nature Communications, 2021, 12, 2965.	5.8	210
139	Beneficial autoimmunity improves cancer prognosis. Nature Reviews Clinical Oncology, 2021, 18, 591-602.	12.5	63
140	Nanoparticle-enabled innate immune stimulation activates endogenous tumor-infiltrating T cells with broad antigen specificities. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	14
141	Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer. Clinical Cancer Research, 2021, 27, 4089-4100.	3.2	46
142	Microenvironmental regulation of tumour immunity and response to immunotherapy. Journal of Pathology, 2021, 254, 374-383.	2.1	17
143	Targeting Solid Tumors Using CD3 Bispecific Antibodies. Molecular Cancer Therapeutics, 2021, 20, 1350-1358.	1.9	8
144	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell, 2021, 39, 632-648.e8.	7.7	230

#	Article	IF	Citations
146	Modelling the interplay between the CD4$$^{+}$$/CD8$$^{+}$$ T-cell ratio and the expression of MHC-I in tumours. Journal of Mathematical Biology, 2021, 83, 2.	0.8	0
147	Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity. Nature Immunology, 2021, 22, 809-819.	7.0	113
148	Symphony of nanomaterials and immunotherapy based on the cancerâ€“immunity cycle. Acta Pharmaceutica Sinica B, 2022, 12, 107-134.	5.7	70
149	The therapeutic potential of multiclonal tumoricidal T cells derived from tumor infiltrating lymphocyte-derived iPS cells. Communications Biology, 2021, 4, 694.	2.0	18
150	Peripheral blood CD45RO+T cells is a predictor of the effectiveness of neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Medicine (United States), 2021, 100, e26214.	0.4	3
151	The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity. Frontiers in Immunology, 2021, 12, 682435.	2.2	27
152	Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer. Current Treatment Options in Oncology, 2021, 22, 69.	1.3	16
153	The Mechanism of CD8+ T Cells for Reducing Myofibroblasts Accumulation during Renal Fibrosis. Biomolecules, 2021, 11, 990.	1.8	8
154	CD8+ T cell differentiation and dysfunction in cancer. Nature Reviews Immunology, 2022, 22, 209-223.	10.6	345
155	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clinical Cancer Research, 2021, 27, 5365-5375.	3.2	29
156	The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients. Frontiers in Immunology, 2021, 12, 701636.	2.2	6
157	The Complement System in Ovarian Cancer: An Underexplored Old Path. Cancers, 2021, 13, 3806.	1.7	5
158	Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing. , 2021, 9, e002595.		31
159	Transcriptomic signatures of tumors undergoing T cell attack. Cancer Immunology, Immunotherapy, 2021, , 1.	2.0	6
160	An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nature Medicine, 2021, 27, 1250-1261.	15.2	159
161	DCision-making in tumors governs T cell anti-tumor immunity. Oncogene, 2021, 40, 5253-5261.	2.6	22
162	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature, 2021, 596, 126-132.	13.7	234
163	Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature, 2021, 596, 119-125.	13.7	239

#	Article	IF	Citations
164	Cytokines, Hormones and Cellular Regulatory Mechanisms Favoring Successful Reproduction. Frontiers in Immunology, 2021, 12, 717808.	2.2	60
166	Tumor Infiltrating Lymphocytes Target HLA-I Phosphopeptides Derived From Cancer Signaling in Colorectal Cancer. Frontiers in Immunology, 2021, 12, 723566.	2.2	14
167	Precision strategies for cancer treatment by modifying the tumor-related bacteria. Applied Microbiology and Biotechnology, 2021, 105, 6183-6197.	1.7	9
168	Targeted TÂcell receptor gene editing provides predictable TÂcell product function for immunotherapy. Cell Reports Medicine, 2021, 2, 100374.	3.3	30
169	Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy. Cancers, 2021, 13, 4245.	1.7	13
170	Significance of bystander T cell activation in microbial infection. Nature Immunology, 2022, 23, 13-22.	7.0	62
171	The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer. Cells, 2021, 10, 2234.	1.8	10
172	TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer. Cancers, 2021, 13, 4394.	1.7	6
173	CXCR6 positions cytotoxic TÂcells to receive critical survival signals in the tumor microenvironment. Cell, 2021, 184, 4512-4530.e22.	13.5	180
174	Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discovery, 2022, 12, 108-133.	7.7	165
176	Antigen dominance hierarchies shape TCF1+ progenitor CD8 TÂcell phenotypes in tumors. Cell, 2021, 184, 4996-5014.e26.	13.5	84
177	Tumour antigen-induced T cell exhaustion â€" the archenemy of immune-hot malignancies. Nature Reviews Clinical Oncology, 2021, 18, 749-750.	12.5	20
178	Harnessing the Immune System to Fight Multiple Myeloma. Cancers, 2021, 13, 4546.	1.7	10
179	Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies Â± other therapies in lung cancer: a systematic review and meta-analysis. European Journal of Hospital Pharmacy, 2023, 30, 3-8.	0.5	9
181	TCR repertoire characteristics predict clinical response to adoptive CTL therapy against nasopharyngeal carcinoma. OncoImmunology, 2021, 10, 1955545.	2.1	6
182	Partial absence of PDâ€1 expression by tumorâ€infiltrating EBVâ€specific CD8⁺ T cells in EBVâ€driven lymphoepitheliomaâ€like carcinoma. Clinical and Translational Immunology, 2020, 9, e1175.	1.7	7
183	Cytotoxic CD8+ Lymphocytes in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1224, 53-62.	0.8	56
184	CAR T Cell Therapy Progress and Challenges for Solid Tumors. Cancer Treatment and Research, 2020, 180, 297-326.	0.2	23

#	Article	IF	Citations
185	CD8+ T cell states in human cancer: insights from single-cell analysis. Nature Reviews Cancer, 2020, 20, 218-232.	12.8	766
190	Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab. , 2020, 8, e001591.		6
191	Î³Î´ T-cell Receptors Derived from Breast Cancerâ€“Infiltrating T Lymphocytes Mediate Antitumor Reactivity. Cancer Immunology Research, 2020, 8, 530-543.	1.6	42
192	Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. Journal of Clinical Investigation, 2019, 129, 4992-5004.	3.9	107
193	Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. Journal of Clinical Investigation, 2020, 130, 1595-1607.	3.9	10
194	Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. Oncotarget, 2020, 11, 2669-2683.	0.8	14
195	Exhausted T cells and epigenetic status. Cancer Biology and Medicine, 2020, 17, 923-936.	1.4	32
196	Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells . OncoTargets and Therapy, 2019, Volume 12, 11033-11044.	1.0	9
197	Single-cell RNA Sequencing in Immunology. Current Genomics, 2020, 21, 564-575.	0.7	14
198	Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma. ELife, 2020, 9, .	2.8	13
199	Cancer systems immunology. ELife, 2020, 9, .	2.8	14
200	CXCR6 by increasing retention of memory CD8⁺ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. , 2021, 9, e003329.		25
201	Coupling programmed cell death 1-positive tumor-infiltrating T cells with anti-programmed cell death 1 antibody improves the efficacy of adoptive T-cell therapy. Cytotherapy, 2021, , .	0.3	2
202	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nature Communications, 2021, 12, 6071.	5.8	44
204	New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma. Cancers, 2021, 13, 5280.	1.7	26
206	Enhancing adoptive CD8 T cell therapy by systemic delivery of tumor associated antigens. Scientific Reports, 2021, 11, 19794.	1.6	6
207	Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-Î³ signaling and tumor-infiltrating lymphocytes. Journal of Hematology and Oncology, 2021, 14, 160.	6.9	37
208	Microbial Colonization and Inflammation as Potential Contributors to the Lack of Therapeutic Success in Oral Squamous Cell Carcinoma. Frontiers in Oral Health, 2021, 2, 739499.	1.2	2

#	Article	IF	Citations
216	Immuno-Oncology of Colorectal Cancer. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 183-204.	0.2	0
217	Myeloid antigen-presenting cell niches sustain antitumor TÂcells and license PD-1 blockade via CD28 costimulation. Cancer Cell, 2021, 39, 1623-1642.e20.	7.7	64
218	Single-Cell Transcriptomic Analysis Reveals a Tumor-Reactive T Cell Signature Associated With Clinical Outcome and Immunotherapy Response In Melanoma. Frontiers in Immunology, 2021, 12, 758288.	2.2	13
219	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. , 2020, 8, .		7
220	Antimetastatic defense by CD8+ T cells. Trends in Cancer, 2022, 8, 145-157.	3.8	12
221	Solid Tumor Microenvironment Can Harbor and Support Functional Properties of Memory T Cells. Frontiers in Immunology, 2021, 12, 706150.	2.2	2
222	The Emerging Interplay Between Recirculating and Tissue-Resident Memory T Cells in Cancer Immunity: Lessons Learned From PD-1/PD-L1 Blockade Therapy and Remaining Gaps. Frontiers in Immunology, 2021, 12, 755304.	2.2	2
223	Tumour-infiltrating bystander CD8⁺T cells activated by IL-15 contribute to tumour control in non-small cell lung cancer. Thorax, 2022, 77, 769-780.	2.7	9
224	Immortalization and functional screening of natively paired human T cell receptor repertoires. Protein Engineering, Design and Selection, 2022, 35, .	1.0	2
225	Biomarkers for predicting the efficacy of immune checkpoint inhibitors. Journal of Cancer, 2022, 13, 481-495.	1.2	12
226	Functional virus-specific memory T cells survey glioblastoma. Cancer Immunology, Immunotherapy, 2022, 71, 1863-1875.	2.0	15
227	Tumor microenvironment-responsive Ag2S-PAsp(DOX)-cRGD nanoparticles-mediated photochemotherapy enhances the immune response to tumor therapy. Biomaterials, 2022, 281, 121328.	5.7	33
228	Isolation of TCR genes with tumor-killing activity from tumor-infiltrating and circulating lymphocytes in a tumor rejection cynomolgus macaque model. Molecular Therapy - Oncolytics, 2022, 24, 77-86.	2.0	3
230	Eudragit S100 prepared pH-responsive liposomes-loaded betulinic acid against colorectal cancer inÂvitro and inÂvivo. Journal of Liposome Research, 2022, 32, 250-264.	1.5	11
231	Comprehensive and Integrative Analysis of Two Novel SARS-CoV-2 Entry Associated Proteases CTSB and CTSL in Healthy Individuals and Cancer Patients. Frontiers in Bioengineering and Biotechnology, 2022, 10, 780751.	2.0	2
232	Bystander CD4⁺ T cells infiltrate human tumors and are phenotypically distinct. OncoImmunology, 2022, 11, .	2.1	13
233	Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 1923-1935.	2.0	19
234	Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade. OncoImmunology, 2022, 11, 2025668.	2.1	6

#	Article	IF	Citations
236	Revealing Clonal Responses of Tumor-Reactive T-Cells Through T Cell Receptor Repertoire Analysis. Frontiers in Immunology, 2022, 13, 807696.	2.2	13
238	PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted TÂcell clonotypes. Cell Reports, 2022, 38, 110331.	2.9	45
239	Antigen cross-presentation in young tumor-bearing hosts promotes CD8 ⁺ T cell terminal differentiation. Science Immunology, 2022, 7, eabf6136.	5.6	5
240	An atlas of intratumoral T cells. Science, 2021, 374, 1446-1447.	6.0	5
241	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39⁺ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. , 2020, 8, e001650.		35
242	Emerging role of bystander T cell activation in autoimmune diseases. BMB Reports, 2022, 55, 57-64.	1.1	21
243	Building the Canadian Bladder Cancer Research Network (CBCRN): Progress During a Pandemic. Canadian Urological Association Journal, 2022, 16, .	0.3	0
244	Regulation of tissue-resident memory T cells by the Microbiota. Mucosal Immunology, 2022, 15, 408-417.	2.7	16
245	Bystander T cells in cancer immunology and therapy. Nature Cancer, 2022, 3, 143-155.	5.7	47
246	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. Cancer Discovery, 2022, 12, 958-983.	7.7	10
247	Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. Cell Research, 2022, 32, 530-542.	5.7	54
248	Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science, 2022, 375, 877-884.	6.0	156
249	Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy. International Journal of Molecular Sciences, 2022, 23, 2594.	1.8	14
250	The Unfolded Protein Response at the Tumor-Immune Interface. Frontiers in Immunology, 2022, 13, 823157.	2.2	11
252	Amplifying natural antitumor immunity for personalized immunotherapy. Cell Research, 2022, , .	5.7	1
253	Isolation of Neoantigen-Specific Human T Cell Receptors from Different Human and Murine Repertoires. Cancers, 2022, 14, 1842.	1.7	2
254	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nature Reviews Clinical Oncology, 2022, 19, 441-457.	12.5	176
255	Two sides of the same coin: Protective versus pathogenic CD4 ⁺ resident memory T cells. Science Immunology, 2022, 7, eabf9393.	5.6	11

#	Article	IF	Citations
256	Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. Seminars in Cancer Biology, 2022, 86, 207-223.	4.3	35
257	Multimodal predictors for precision immunotherapy. Immuno-Oncology Technology, 2022, 14, 100071.	0.2	4
259	Cancer-immunotherapy biomarkers in the tumor microenvironment. Okayama Igakkai Zasshi, 2021, 133, 151-157.	0.0	0
260	T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes. Nature Biotechnology, 2022, 40, 488-498.	9.4	12
262	Triterpenoids of Rhus chinensis Supressed Colorectal Cancer Progress by Enhancing Antitumor Immunity and CD8â€‰+â€‰T Cells Tumor Infiltration. Nutrition and Cancer, 2022, 74, 2550-2564.	0.9	3
263	PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors. Journal of Clinical Investigation, 2022, 132, .	3.9	37
265	Neoantigen-specific CD4+ TÂcells in human melanoma have diverse differentiation states and correlate with CD8+ TÂcell, macrophage, and B cell function. Cancer Cell, 2022, 40, 393-409.e9.	7.7	59
266	Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers. Cancer Cell, 2022, 40, 410-423.e7.	7.7	47
267	Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions. Expert Opinion on Biological Therapy, 2022, 22, 627-641.	1.4	19
271	A variety of â€˜exhaustedâ€™ T cells in the tumor microenvironment. International Immunology, 2022, 34, 563-570.	1.8	13
272	Emerging role of bystander T cell activation in autoimmune diseases.. BMB Reports, 2022, , .	1.1	0
273	Establishment and Application of a Prognostic Risk Score Model Based on Characteristics of Different Immunophenotypes for Lung Adenocarcinoma. Frontiers in Genetics, 2022, 13, 850101.	1.1	0
274	Predictive value of intraâ€tumoural TCRÎ² rearrangements in precisely selecting adjuvant therapy for EGFR â€mutant nonâ€smallâ€cell lung cancer. Clinical and Translational Discovery, 2022, 2, .	0.2	1
275	The mutual relationship between the host immune system and radiotherapy: stimulating the action of immune cells by irradiation. International Journal of Clinical Oncology, 2023, 28, 201-208.	1.0	1
276	Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 172.	3.5	2
277	An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes. Cancer Cell, 2022, 40, 524-544.e5.	7.7	23
278	Dual drugs decorated bacteria irradiate deep hypoxic tumor and arouse strong immune responses. Biomaterials, 2022, 286, 121582.	5.7	24
279	Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy. International Review of Cell and Molecular Biology, 2022, , 163-192.	1.6	3

#	Article	IF	Citations
282	Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends in Immunology, 2022, 43, 523-545.	2.9	176
283	The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry. Frontiers in Oncology, 0, 12, .	1.3	0
284	Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments. Immuno-Oncology Technology, 2022, 15, 100090.	0.2	1
285	Crosstalk of RNA Adenosine Modification-Related Subtypes, Establishment of a Prognostic Model, and Immune Infiltration Characteristics in Ovarian Cancer. Frontiers in Immunology, 0, 13, .	2.2	8
286	Sarcoma Common MHC-I Haplotype Restricts Tumor-Specific CD8+ T Cell Response. Cancers, 2022, 14, 3414.	1.7	7
287	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. Cancer Research Communications, 2022, 2, 739-753.	0.7	2
288	Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer. Cancer Research, 2022, 82, 3588-3602.	0.4	12
289	The evolving role of tissue-resident memory T cells in infections and cancer. Science Advances, 2022, 8, .	4.7	42
290	Signatures of recent activation identify a circulating T cell compartment containing tumor-specific antigen receptors with high avidity. Science Immunology, 2022, 7, .	5.6	8
291	CD39 ⁺ tissue-resident memory CD8 ⁺ T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer. Science Immunology, 2022, 7, .	5.6	23
293	Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages. Cancer Research, 2022, 82, 3785-3801.	0.4	9
294	Ligand Identification for Orphan MHC-Agnostic T-Cell Receptors by Whole Genome CRISPRâ€“Cas9 Screening. Methods in Molecular Biology, 2022, , 3-14.	0.4	0
295	An Artificial Intelligence-Based Ecological Index for Prognostic Evaluation of Colorectal Cancer. SSRN Electronic Journal, 0, , .	0.4	0
296	Single-cell and spatial transcriptome analyses revealed cell heterogeneity and immune environment alternations in metastatic axillary lymph nodes in breast cancer. Cancer Immunology, Immunotherapy, 2023, 72, 679-695.	2.0	7
297	Keeping track of the T cells that matter. Nature Cancer, 2022, 3, 1015-1017.	5.7	1
298	TCR repertoire and transcriptional signatures of circulating tumourâ€associated T cells facilitate effective nonâ€invasive cancer detection. Clinical and Translational Medicine, 2022, 12, .	1.7	2
299	Technology meets TILs: Deciphering TÂcell function in the -omics era. Cancer Cell, 2023, 41, 41-57.	7.7	17
300	Translational Research in Cancer Immunotherapies. Japanese Journal of Lung Cancer, 2022, 62, 363-370.	0.0	0

#	Article	IF	Citations
301	Next generation TÂcell therapies for solid cancers. Med, 2022, 3, 645-647.	2.2	0
302	Enhancing the Antitumor Immunity of T Cells by Engineering the Lipid-Regulatory Site of the TCR/CD3 Complex. Cancer Immunology Research, 2023, 11, 93-108.	1.6	3
304	Evolution and modulation of antigen-specific T cell responses in melanoma patients. Nature Communications, 2022, 13, .	5.8	10
305	Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models. Journal of the National Cancer Center, 2022, 2, 263-276.	3.0	9
306	Nanobody-based CAR T cells targeting intracellular tumor antigens. Biomedicine and Pharmacotherapy, 2022, 156, 113919.	2.5	7
307	GZMKhigh CD8+ T effector memory cells are associated with CD15high neutrophil abundance in non-metastatic colorectal tumors and predict poor clinical outcome. Nature Communications, 2022, 13, .	5.8	13
308	T cells specific for Î±-myosin drive immunotherapy-related myocarditis. Nature, 2022, 611, 818-826.	13.7	100
309	Cancer Immunology and Immunotherapy: From Defining Basic Immunology to Leading the Fight Against Cancer. Immunological Investigations, 2022, 51, 2128-2132.	1.0	2
310	Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy. Frontiers in Immunology, 0, 13, .	2.2	2
311	Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia. Experimental Hematology and Oncology, 2022, 11, .	2.0	4
312	Boosting the Immunoactivity of T Cells by Resonant Thermal Radiation from Electric Graphene Films for Improved Cancer Immunotherapy. Advanced Therapeutics, 2023, 6, .	1.6	3
313	Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer. Gynecologic Oncology, 2023, 168, 135-143.	0.6	0
314	Recruiting T cells and sensitizing tumors to NKG2D immune surveillance for robust antitumor immune response. Journal of Controlled Release, 2023, 353, 943-955.	4.8	0
315	Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells. Cancer Immunology, Immunotherapy, 0, , .	2.0	1
316	Targeting the activity of T cells by membrane surface redox regulation for cancer theranostics. Nature Nanotechnology, 2023, 18, 86-97.	15.6	24
317	The role of interferons in ovarian cancer progression: Hinderer or promoter?. Frontiers in Immunology, 0, 13, .	2.2	4
318	The common HLA class I-restricted tumor-infiltrating T cell response in HPV16-induced cancer. Cancer Immunology, Immunotherapy, 0, , .	2.0	3
319	Use of intercellular proximity labeling to quantify and decipher cell-cell interactions directed by diversified molecular pairs. Science Advances, 2022, 8, .	4.7	11

#	Article	IF	Citations
321	The ectonucleotidase CD39 identifies tumor-reactive CD8+ TÂcells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity, 2023, 56, 93-106.e6.	6.6	24
322	Ginsenoside Rg3 nanoparticles with permeation enhancing based chitosan derivatives were encapsulated with doxorubicin by thermosensitive hydrogel and anti-cancer evaluation of peritumoral hydrogel injection combined with PD-L1 antibody. Biomaterials Research, 2022, 26, .	3.2	14
323	Immunotherapies targeting neoantigens are effective in <scp>PD</scp>â€1 blockadeâ€resistant tumors. International Journal of Cancer, 2023, 152, 1463-1475.	2.3	2
324	T-cell repertoire diversity: friend or foe for protective antitumor response?. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	11
325	Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers. Current Opinion in Oncology, 2023, 35, 107-113.	1.1	4
326	Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens. Nature Biotechnology, 2023, 41, 783-787.	9.4	10
327	Neoantigens: promising targets for cancer therapy. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	112
328	CTLAâ€4 inhibition facilitates follicular Tâ€B cell interaction and the production of tumorâ€specific antibodies. International Journal of Cancer, 0, , .	2.3	1
329	Biomarkers of tumor-reactive CD4⁺and CD8⁺TILs associate with improved prognosis in endometrial cancer.. , 2022, 10, e005443.		12
330	Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis. Immunotherapy, 2023, 15, 189-207.	1.0	3
331	Immunosuppressive microenvironment improvement and treatment of aggressive malignancy pancreatic ductal adenocarcinoma based on local administration of injectable hydrogel. Nano Today, 2023, 50, 101832.	6.2	9
332	TCR sequencing: applications in immuno-oncology research. Immuno-Oncology Technology, 2023, 17, 100373.	0.2	3
333	The potential role of the thymus in immunotherapies for acute myeloid leukemia. Frontiers in Immunology, 0, 14, .	2.2	4
334	Cold atmospheric plasma: Novel opportunities for tumor microenvironment targeting. Cancer Medicine, 2023, 12, 7189-7206.	1.3	6
336	A Novel Cell-based Luciferase Reporter Platform for the Development and Characterization of T-Cell Redirecting Therapies and Vaccine Development. Journal of Immunotherapy, 2023, 46, 96-106.	1.2	1
337	T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control. Nature Immunology, 2023, 24, 664-675.	7.0	26
338	Immortalized B Cells Transfected with mRNA of Antigen Fused to MITD (IBMAM): An Effective Tool for Antigen-Specific T-Cell Expansion and TCR Validation. Biomedicines, 2023, 11, 796.	1.4	4
339	T-Cell Repertoire Analysis in the Conjunctiva of Murine Dry Eye Model. , 2023, 64, 14.		0

#	Article	IF	Citations
340	Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. Nature, 2023, 615, 697-704.	13.7	44
342	The pre-existing TÂcell landscape determines the response to bispecific TÂcell engagers in multiple myeloma patients. Cancer Cell, 2023, 41, 711-725.e6.	7.7	40
343	Expression pattern, tumor immune landscape, and prognostic value of N7â€'methylguanosine regulators in bladder urothelial carcinoma. Oncology Letters, 2023, 25, .	0.8	1
344	Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire. Cancer Immunology, Immunotherapy, 2023, 72, 2375-2392.	2.0	2
345	Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma. Frontiers in Immunology, 0, 14, .	2.2	2
347	Dynamics and specificities of T cells in cancer immunotherapy. Nature Reviews Cancer, 2023, 23, 295-316.	12.8	49
349	Immune-Related Genesâ€™ Prognostic, Therapeutic and Diagnostic Value in Ovarian Cancer Immune-Related Gene Biomarker in Ovarian Cancer. Cancer Control, 2023, 30, 107327482311687.	0.7	1
350	The â€œGreat Debateâ€•at Immunotherapy Bridge 2022, Naples, November 30thâ€“December 1st, 2022. Journal of Translational Medicine, 2023, 21, .	1.8	0
358	T cells in health and disease. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	36
365	Harnessing 3D in vitro systems to model immune responses to solid tumours: a step towards improving and creating personalized immunotherapies. Nature Reviews Immunology, 2024, 24, 18-32.	10.6	2
377	Stem-like exhausted and memory CD8+ T cells in cancer. Nature Reviews Cancer, 2023, 23, 780-798.	12.8	5
392	T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nature Reviews Drug Discovery, 2023, 22, 996-1017.	21.5	7
403	Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nature Reviews Clinical Oncology, 2024, 21, 173-184.	12.5	0
411	Important Biomarkers for Better Evaluation of Checkpoint Inhibitors and Other Immunotherapies in Lung Cancer. , 2024, , 331-351.		0